Pillstats
Rx only · Injection · Intravenous

Nicardipine Hydrochloride

Nicardipine Hydrochloride

11 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US17 NDCs
11 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)7396
US makers11 labelers
Packages19
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1583164746332025 Q12025 Q22025 Q32025 Q42026 Q1
238
Rx · 2026 Q1
11K
Units dispensed
-54%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it11 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Hikma Pharmaceuticals USA Inc.unknown4SUPPLYING
Caplin Steriles Limitedunknown2SUPPLYING
Cipla USA Inc.unknown2SUPPLYING
Somerset Therapeutics, LLCunknown2SUPPLYING
Chengdu Shuode Pharmaceutical Co., Ltdunknown2SUPPLYING
Fresenius Kabi USA, LLCunknown2SUPPLYING
HF Acquisition Co LLC, DBA HealthFirstunknown1SUPPLYING
Micro Labs Limitedunknown1SUPPLYING
West-Ward Pharmaceuticals Corpunknown1SUPPLYING
Armas Pharmaceuticals Inc.unknown1SUPPLYING
Lifestar Pharma LLCunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • May 13, 2013
    RECALLRecall (Class III): Nicardipine Hydrochloride Injection 25 mg/10 mL (2.5 mg/mL), 10 mL single-use vials, Rx Only, Mfd. by Exela Pharma Scie…

    Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D) — Recalling firm: West-ward Pharmaceutical Corp. — Nationwide